Is serum thyroglobulin a useful marker for thyroid cancer in patients who have not had ablation of residual thyroid tissue?

Thyroid

Volumn 7, Issue 3, 1997, Pages 343-346

  Van Wyngaarden, Kors ^a   McDougall, I Ross ^b,c  

^a LEIDEN UNIVERSITY   (Netherlands)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THYROGLOBULIN;

ADOLESCENT; ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CANCER RECURRENCE; CANCER RISK; CERVICAL LYMPH NODE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; HUMAN; IMMUNORADIOMETRIC ASSAY; LOBECTOMY; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; THYROID CANCER; THYROIDECTOMY;

EID: 12644250123     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.1997.7.343     Document Type: Article

References (31)

1. Woolner LB, Beahrs OH, Black BM, McConahey WM, Keating FR JR 1961 Classification and prognosis of thyroid carcinoma: A study of 885 cases observed in a thirty year period. Am J Surg 102:354-387.
2. Simpson WJ, McKinney SE, Carruthers JS, Gospodarowicz MK, Sutcliffe, SB, Panzarella T 1987 Papillar and follicular thyroid cancer: Prognostic factors in 1,578 patients. Am J Med 83:479-488.
3. Hay ID 1989 Prognostic factors in thyroid cancer. Thyroid Today XII:1-9.
4. Hay ID 1990 Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 19:545-576.
5. Lang W, Choritz H, Hungeshagen H 1986 Risk factors in follicular thyroid carcinomas. A retrospective follow-up study covering a 14 year period with emphasis on morphologic findings. Am J Surg Pathol 10:246-255.
6. Wingo PA, Tong T, Bolden S 1995 Cancer Statistics Ca 45:8-30.
7. Mazzaferri EL, Young RL 1981 Papillary thyroid carcinoma: A 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 70:511-518.
8. Mazzaferri EL, Jiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular cancer. Am J Med 89:418-428.
9. Baldet L, Manderscheid J-C, Glinoer D, Jaffiol C, Coste-Seignovert B, Percheron C 1989 The management of differentiated thyroid cancer in Europe in 1988: results of an international survey. Acta Endocrinol (Copenh) 120:547-558.
10. Van de Velde CJH, Hamming JF, Goslings BM, Schelfhout LJDM, Clark OH, Smeds S, Bruining HA, Krenning EP, Cady B 1988 Report of the consensus development conference on the management of differentiated thyroid cancer in the Netherlands. Eur J Cancer Clin Oncol 24:287-292.
11. Pochin EE 1969 Long-term hazards of radioiodine treatment of thyroid carcinoma. In: Hedinger C (ed) UICC Monograph Series, Vol. 12, Thyroid Cancer. Springer-Verlag, Berlin, pp. 293-304.
12. Hall P, Boice JD Jr, Berg G, Bielkengren G, Ericsson U-B, Hallquist A, Lidberg M, Lundell G, Mattsson A, Tennvall J, Wiklund K, Holm L-E 1992 Leukaemia incidence after iodine-131 exposure. Lancet 340:1-4.
13. 131) treatment for thyroid carcinoma. Postgrad Med 61:361-362.
14. Rall JE, Alpers JB, Lewallen GG, Sonenberg M, Berman M, Rawson RW 1957 Radiation pneumonitis and fibrosis: a complication of radioiodine treatment of pulmonary metastases from cancer of the thyroid. J Clin Endocrinol Metab 17:1263-1276.
15. 131I in the treatment of thyroid cancer. Thyroid Today Edited by JH Oppenheimer XVI:1-9.
16. Bayer MF, McDougall IR 1984 Differences in radioimmunoassay results for thyroglobulin that effect management of patients with thyroid cancer. Clin Chem 30:81-86.
17. Bayer MF, McDougall IR, Kriss JP 1987 Retrospective study of thyroglobulin measurements performed in patients with differentiated thyroid carcinoma at the Stanford University thyroid clinic between 1979 and 1985. In: Hufner M, Reiners C (eds) Thyroglobulin and Thyroglobulin Antibodies in the Follow-up of Thyroid Cancer and Endemic Goiter. George Thieme Verlag, Stuttgart, pp. 104-111.
18. 131I treatment on thyroglobulin measurements in the follow-up of patients with thyroid cancer. Thyroid 4:239-242.
19. Schaadt B, Feldt-Rasmussen U, Rasmusson B, Tørring H, Foder B, Jørgensen K, Hansen HS 1995 Assessment of the influence of thyroglobulin (Tg) autoantibodies and other interfering factors on the use of serum Tg as tumor marker in differentiated thyroid carcinoma. Thyroid 5:165-170.
20. Van Herle AJ 1981 Serum thyroglobulin measurement in the diagnosis and management of thyroid disease. Thyroid Today. 4:1-5.
21. Mazzaferri EL 1995 Treating high thyroglobulin with radioiodine: A magic bullet or a shot in the dark. J Clin Endocrinol Metabol 80:1485-1487.
22. Bayer MF, McDougall IR 1980 Radioimmunoassay of free thyroxine in serum. Comparison with clinical findings and results of conventional thyroid function. Clin Chem 26:1186-1192.
23. Bayer MF, Kriss JP, McDougall IR 1985 Clinical experience with sensitive thyrotropin measurements. Diagnostic and therapeutic implications. J Nucl Med 26:1248-56.
24. McDougall IR, Maclin N 1995 Hypothyroid women need more thyroxine when pregnant. J Fam Pract 41:238-240.
25. Bayer MF, Kriss JP 1979 Immunoradiometric assay for serum thyroglobulin: semiquantitative measurement of thyroglobulin in anti-thyroglobulin positive serum. J Clin Endocrinol Metab 49:557-564.
26. Mori T, Kriss JP 1971 Measurement by competitive binding radioassay of serum anti-microsomal and anti-thyroglobulin antibodies in Graves' disease and other thyroid disorders. J Clin Endocrinol Metab 33:688-698.
27. Freeman M, Giuliani M, Schwartz E, Gomprecht RF 1969 Acute thyroiditis, thyroid crisis, and hypocalcemia following radioactive iodine therapy. NY State J Med 69:2036-2041.
28. Allweiss P, Braunstein GD, Katz A, Waxman A 1984 Sialadenitis following I-131 therapy for thyroid carcinoma: Concise communication. J Nucl Med 25:755-758.
29. Van Wyngaarden KE, McDougall IR 1996 What is the role, of 1,100 Mbq (<30 mCi) radioiodine I-131 in the treatment of patients with differentiated thyroid cancer? Nucl Med Commun 17:199-207.
30. Van Herle AJ, Uller RP, Mathews NL, Brown J. 1973 Radioimmunoassay for measurement of thyroglobulin in human serum. J Clin Invest 52:1320-1327.
31. Van Herle, Uller RP 1975 Elevated serum thyroglobulin: A marker of metastases in differentiated thyroid carcinoma. J Clin Invest 56:272-277.